Cargando…

Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters

BACKGROUND/AIM: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, which has been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationship with metabolic parameters in pso...

Descripción completa

Detalles Bibliográficos
Autores principales: KORKMAZ, Selma, SAYILAN ÖZGÜN, Gülben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350829/
https://www.ncbi.nlm.nih.gov/pubmed/30762319
http://dx.doi.org/10.3906/sag-1712-192
_version_ 1783557342209507328
author KORKMAZ, Selma
SAYILAN ÖZGÜN, Gülben
author_facet KORKMAZ, Selma
SAYILAN ÖZGÜN, Gülben
author_sort KORKMAZ, Selma
collection PubMed
description BACKGROUND/AIM: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, which has been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationship with metabolic parameters in psoriasis vulgaris patients both with and without metabolic syndrome (MetS). MATERIALS AND METHODS: Fifty-three patients and 26 healthy controls were included in this study. Serum adropin levels, fasting blood glucose, fasting serum insulin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and triglyceride levels of all participants were analyzed. Enzyme-linked immunosorbent assay was used to measure serum adropin levels.  RESULTS: Serum adropin levels were 2.94 ± 0.56 ng/mL in psoriatic patients without MetS, 2.49 ± 0.77 ng/mL in psoriasis patients with MetS, and 3.37 ± 0.71 ng/mL in the control group. Multivariate logistic regression analysis was used to evaluate adropin decreases in psoriasis patients as an independent predictor of the presence of MetS.  CONCLUSION: The serum levels of adropin in psoriasis patients were significantly lower in the presence of MetS, and this decrease was more prominent than in those without MetS. Adropin may be a contributing factor for metabolic disorders and the development of MetS in psoriasis patients. 
format Online
Article
Text
id pubmed-7350829
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Scientific and Technological Research Council of Turkey
record_format MEDLINE/PubMed
spelling pubmed-73508292020-07-13 Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters KORKMAZ, Selma SAYILAN ÖZGÜN, Gülben Turk J Med Sci Article BACKGROUND/AIM: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, which has been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationship with metabolic parameters in psoriasis vulgaris patients both with and without metabolic syndrome (MetS). MATERIALS AND METHODS: Fifty-three patients and 26 healthy controls were included in this study. Serum adropin levels, fasting blood glucose, fasting serum insulin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and triglyceride levels of all participants were analyzed. Enzyme-linked immunosorbent assay was used to measure serum adropin levels.  RESULTS: Serum adropin levels were 2.94 ± 0.56 ng/mL in psoriatic patients without MetS, 2.49 ± 0.77 ng/mL in psoriasis patients with MetS, and 3.37 ± 0.71 ng/mL in the control group. Multivariate logistic regression analysis was used to evaluate adropin decreases in psoriasis patients as an independent predictor of the presence of MetS.  CONCLUSION: The serum levels of adropin in psoriasis patients were significantly lower in the presence of MetS, and this decrease was more prominent than in those without MetS. Adropin may be a contributing factor for metabolic disorders and the development of MetS in psoriasis patients.  The Scientific and Technological Research Council of Turkey 2019-02-11 /pmc/articles/PMC7350829/ /pubmed/30762319 http://dx.doi.org/10.3906/sag-1712-192 Text en Copyright © 2019 The Author(s) This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Article
KORKMAZ, Selma
SAYILAN ÖZGÜN, Gülben
Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters
title Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters
title_full Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters
title_fullStr Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters
title_full_unstemmed Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters
title_short Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters
title_sort serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350829/
https://www.ncbi.nlm.nih.gov/pubmed/30762319
http://dx.doi.org/10.3906/sag-1712-192
work_keys_str_mv AT korkmazselma serumadropinlevelsinpsoriasisvulgarisanditsrelationwithmetabolicparameters
AT sayilanozgungulben serumadropinlevelsinpsoriasisvulgarisanditsrelationwithmetabolicparameters